Canopus BioPharma Incorporated
Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. It also provides antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceutricals. The company was founded in 1996 as Canopus Corporation and chan… Read more
Canopus BioPharma Incorporated (CBIA) - Net Assets
Latest net assets as of May 2023: $-184.96K USD
Based on the latest financial reports, Canopus BioPharma Incorporated (CBIA) has net assets worth $-184.96K USD as of May 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.15K) and total liabilities ($191.11K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-184.96K |
| % of Total Assets | -3005.93% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Canopus BioPharma Incorporated - Net Assets Trend (2013–2022)
This chart illustrates how Canopus BioPharma Incorporated's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Canopus BioPharma Incorporated (2013–2022)
The table below shows the annual net assets of Canopus BioPharma Incorporated from 2013 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-08-31 | $-13.28K | +97.55% |
| 2014-08-31 | $-542.70K | +79.42% |
| 2013-08-31 | $-2.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Canopus BioPharma Incorporated's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 890164100.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (August 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.22K | % |
| Other Comprehensive Income | $753.17K | % |
| Total Equity | $-13.28K | 100.00% |
Canopus BioPharma Incorporated Competitors by Market Cap
The table below lists competitors of Canopus BioPharma Incorporated ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Snoogoo Corp
PINK:SGOO
|
$0.96 |
|
Medican Enterprises
PINK:MDCN
|
$0.96 |
|
SFLMaven Corp
PINK:SFLM
|
$0.96 |
|
Avix Technologies Inc
PINK:AVIX
|
$0.96 |
|
Nexity Financial Corporation
PINK:NXTYQ
|
$0.96 |
|
Greyson International Inc
PINK:GYSN
|
$0.96 |
|
Newron Sport
PINK:NSPT
|
$0.96 |
|
Outback Oil & Mineral Exploration Corp
PINK:OUTB
|
$0.96 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Canopus BioPharma Incorporated's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 900 to -13,282, a change of -14,182 (-1575.8%).
- Net loss of 764,708 reduced equity.
- Other comprehensive income increased equity by 750,526.
- Other factors decreased equity by 0.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-764.71K | -5757.48% |
| Other Comprehensive Income | $750.53K | +5650.7% |
| Total Change | $- | -1575.78% |
Book Value vs Market Value Analysis
This analysis compares Canopus BioPharma Incorporated's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-08-31 | $-0.13 | $0.00 | x |
| 2014-08-31 | $-0.01 | $0.00 | x |
| 2021-08-31 | $0.00 | $0.00 | x |
| 2022-08-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Canopus BioPharma Incorporated utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-48.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-262.29K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-796.67K |
| 2021 | -195.00% | 0.00% | 0.00x | 1.00x | $-1.84K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-763.38K |
Industry Comparison
This section compares Canopus BioPharma Incorporated's net assets metrics with peer companies in the Advertising Agencies industry.
Industry Context
- Industry: Advertising Agencies
- Average net assets among peers: $245,455,576
- Average return on equity (ROE) among peers: 1.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Canopus BioPharma Incorporated (CBIA) | $-184.96K | 0.00% | N/A | $0.96 |
| Adaptive Ad Systems Inc (AATV) | $4.67 Million | 44.68% | 0.14x | $1.69K |
| ACCESS Newswire Inc. (ACCS) | $1.85 Million | 16.56% | 0.38x | $14.25 Million |
| Artec Consulting Corp (ACTL) | $-1.09 Million | 0.00% | 0.00x | $69.28K |
| Advantage Solutions Inc (ADV) | $2.58 Billion | 2.11% | 1.27x | $109.73 Million |
| Airnet Technology Inc (ANTE) | $3.61 Million | -66.61% | 0.77x | $46.30 Million |
| Applovin Corp (APP) | $-158.24 Million | 0.00% | 0.00x | $111.19 Billion |
| Advantex Marketing International Inc (ATXMF) | $-9.17 Million | 0.00% | 0.00x | $36.32K |
| Baosheng Media Group Holdings Ltd (BAOS) | $41.66 Million | 16.67% | 1.24x | $2.49 Million |
| Bang Holdings Corp (BXNG) | $251.17K | -0.45% | 1.37x | $406.52 |
| Beyond Commerce Inc (BYOC) | $-11.28 Million | 0.00% | 0.00x | $1.65 Million |